DVA
DaVita
$209.68
▲ 0.9%Updated Today 7:15 PM ET
▲ Up 53.1% over the last 12 months
Market Cap
$13.35B
P/E
17.11x
Forward P/E (est.)
16.05x
ROE
181.2%
Revenue Growth
6.7%
EPS Growth
6.6%
Profit Margin
5.7%
FCF Yield
8.2%
Debt / Equity
77.99x
ROIC
21.0%
Interest Coverage
—
Current Ratio
1.42x
Dividend Yield
—
Implied Growth (rev. DCF)
-0.7%
Rating Score
53/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what DVA's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. DVA trades near $209.68, above its 50-day average ($179.12) and 200-day average ($141.98). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 67 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. DVA's is $5.75 (~2.7% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month DVA found buyers near $186.61 (support) and sellers near $213.44 (resistance); its 52-week range is $101.00–$213.44. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.8× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
DaVita (DVA) is a large-cap company in the Health Care Services industry, part of the Health Care sector of the S&P 500, with a market value around $13.35B.
In its latest reported year it generated about $13.64B in revenue and $746.80M in net profit.
Our model rates DVA Neutral (53/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
4.1%
Revenue moved from $11.62B in 2021 to $13.64B in 2025, a 4.1% compound annual growth rate. The most recent year grew a steady 6.7% year over year. Slower, mature growth is common for established businesses.
Gross Margin
32.5%
Operating Margin
15.0%
Net Margin
5.5%
ROE
181.2%
DaVita keeps about 5.7% of each sales dollar as net profit, with a 32.5% gross margin and 15.0% operating margin. Return on equity is 181.2% and return on invested capital about 21.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$8.50B
Net Debt
$7.86B
Net Debt / EBITDA
3.85x
Debt / Equity
77.99x
Leverage: debt-to-equity is 78.0x, with a current ratio of 1.4x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $8.50B of total debt against $644.24M of cash.
Operating CF
$1.89B
Free Cash Flow
$1.31B
FCF Margin
9.6%
In the latest year DaVita produced about $1.89B of operating cash flow and $1.31B of free cash flow after capital spending. That is a free-cash-flow yield of about 8.2% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
17.11x
P/S
0.98x
P/B
—
EV / EBITDA
7.73x
DVA trades at 17.1x trailing earnings (about 16.0x on estimated forward earnings), 1.0x sales. Reverse-engineering today's price implies the market expects roughly -0.7% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How DVA stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), DVA ranks #28 of 59 by our overall rating. It trades at a discount versus the sector on earnings (17.1x P/E vs. 25.4x median) with a higher return on equity (181.2% vs. 14.9%) and slower revenue growth (6.7% vs. 7.9%).
P/E vs sector
17.1x
median 25.4x
ROE vs sector
181.2%
median 14.9%
Growth vs sector
6.7%
median 7.9%
Sector rank
#28
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$149.03 – $253.35
vs. $209.68 today · expected CAGR -7% – 4%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $14.60B | $15.62B | $16.71B | $17.88B | $19.14B |
| Net income | $729.90M | $781.00M | $835.67M | $894.16M | $956.76M |
| EPS | $11.37 | $12.17 | $13.02 | $13.93 | $14.90 |
| Share price (low) | $113.69 | $121.65 | $130.17 | $139.28 | $149.03 |
| Share price (high) | $193.28 | $206.81 | $221.28 | $236.77 | $253.35 |
| CAGR (low–high) | -46% / -8% | -24% / -1% | -15% / 2% | -10% / 3% | -7% / 4% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for DVA:
- Strong return on equity (181.2%) shows capital is put to work well.
- Healthy free-cash-flow yield (~8.2%) funds buybacks and dividends.
The case against DVA:
- Elevated leverage (debt/equity 78.0x) adds financial risk.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Balance-sheet risk — debt/equity of 78.0x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: DaVita is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 17.1x earnings, which our model scores Neutral (53/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.